We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals
BMRN

438 hedge funds and large institutions have $15.8B invested in BioMarin Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 78 funds opening new positions, 150 increasing their positions, 145 reducing their positions, and 44 closing their positions.

New
Increased
Maintained
Reduced
Closed

77% more first-time investments, than exits

New positions opened: 78 | Existing positions closed: 44

34% more call options, than puts

Call options by funds: $208M | Put options by funds: $155M

33% more funds holding in top 10

Funds holding in top 10: 9 → 12 (+3)

7% more funds holding

Funds holding: 411 → 438 (+27)

1.4% more ownership

Funds ownership: 99.72% → 101.12% (+1.4%)

3% more repeat investments, than reductions

Existing positions increased: 150 | Existing positions reduced: 145

3% less capital invested

Capital invested by funds: $16.3B → $15.8B (-$449M)

Holders
438
Holders Change
+27
Holders Change %
+6.57%
% of All Funds
9.93%
Holding in Top 10
12
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+33.33%
% of All Funds
0.27%
New
78
Increased
150
Reduced
145
Closed
44
Calls
$208M
Puts
$155M
Net Calls
+$52.8M
Net Calls Change
+$34.5M

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$146M
2
BlackRock
BlackRock
New York
+$81.5M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$60M
4
Citadel Advisors
Citadel Advisors
Florida
+$58.4M
5
Capital Research Global Investors
Capital Research Global Investors
California
+$56.5M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$178M
2
SIG
Senator Investment Group
New York
-$65.1M
3
O
OrbiMed
New York
-$55.9M
4
Jennison Associates
Jennison Associates
New York
-$43.9M
5
Bank of America
Bank of America
North Carolina
-$43.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
RIA
201
RPG Investment Advisory
California
$1.53M -$26.1K -300 -2%
OPPM
202
Opus Point Partners Management
New York
$1.53M -$244K -2,808 -14%
NIPH
203
NN Investment Partners Holdings
Netherlands
$1.51M -$773K -8,893 -34%
JGGDR
204
JGP Global Gestao de Recursos
Brazil
$1.51M -$133K -1,529 -8%
QF
205
QVT Financial
New York
$1.42M +$2.78K +32 +0.2%
Rafferty Asset Management
206
Rafferty Asset Management
New York
$1.41M -$103K -1,180 -7%
AAM
207
Advisors Asset Management
Colorado
$1.4M -$40.7K -468 -3%
CIBC Asset Management
208
CIBC Asset Management
Ontario, Canada
$1.31M +$118K +1,357 +10%
Truist Financial
209
Truist Financial
North Carolina
$1.3M +$1.39K +16 +0.1%
PIM
210
Platinum Investment Management
Australia
$1.23M – – –
MLICM
211
Metropolitan Life Insurance Company (MetLife)
New York
$1.16M -$10.6K -122 -0.9%
CWM
212
CIBC World Markets
New York
$1.16M -$1.74K -20 -0.2%
Jane Street
213
Jane Street
New York
$1.14M +$1.11M +12,751 New
CG
214
Cutler Group
California
$1.12M -$47.4K -545 -4%
Mariner
215
Mariner
Kansas
$1.12M +$1.09M +12,532 New
M&T Bank
216
M&T Bank
New York
$1.1M -$103K -1,179 -9%
LPL Financial
217
LPL Financial
California
$1.1M -$121K -1,393 -10%
SCM
218
Shelton Capital Management
Colorado
$1.09M – – –
SMDAM
219
Sumitomo Mitsui DS Asset Management
Japan
$1.07M -$21.7K -250 -2%
LCM
220
Landscape Capital Management
New Jersey
$1.06M +$1.03M +11,901 New
EIM
221
Essex Investment Management
Massachusetts
$1.05M +$232K +2,663 +29%
PG
222
Pendal Group
Australia
$1.03M +$44.5K +512 +5%
Simplex Trading
223
Simplex Trading
Illinois
$1.02M +$998K +11,482 New
Mirae Asset Global Investments
224
Mirae Asset Global Investments
South Korea
$1.01M +$89.6K +1,030 +10%
NAM
225
Nissay Asset Management
Japan
$1.01M +$987K +11,351 New
7 8
9
10 11

BMRN Hedge Fund Activity: Q4 2017 in Review

438 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2017, worth a combined $15.8B — down 2.8% from $16.3B a quarter earlier.

Buyers outnumbered sellers: 78 funds opened new BMRN positions and 44 closed out — a net gain of 34 holders — while 150 added to existing stakes and 145 trimmed.

The largest buyer was Baker Bros. Advisors, adding an estimated $146M. The largest seller was Fidelity Investments, cutting an estimated $178M.

  • 438 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2017, up from 411 in Q3 2017.
  • Funds reported $15.8B of BioMarin Pharmaceuticals stock for Q4 2017, down 2.8% quarter-over-quarter.
  • 78 funds opened new BioMarin Pharmaceuticals positions in Q4 2017 and 44 closed out, a net change of +34 holders.
  • The largest BioMarin Pharmaceuticals buyer in Q4 2017 was Baker Bros. Advisors, an estimated $146M added.
  • The largest BioMarin Pharmaceuticals seller in Q4 2017 was Fidelity Investments, an estimated $178M sold.

Based on aggregated 13F filings for Q4 2017.